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Welcome to our Autumn
2006 edition of the 
ESRC Genomics Network
Newsletter.
In this issue, you’ll read four perspectives from across
the Genomics Network on the importance of public
engagment (p 12), explore the issues associated with
genetic databanking (p 6) and find out how genomic
technology can help us understand the threat avian flu
poses to global health (p4). We also look at what
makes genetic tests special (p 24), and have you heard
of ‘Metabolic Syndrome’? According to some experts it
has become a significant public health issue, but what
do we really know about it, and does the condition
actually exist (p20)?
As always, we’d like to hear what you think.
Please send letters, comments or content suggestions
to: gnn@ed.ac.uk or write to: 
Genomics Network Newsletter,




Published by: ESRC Genomics Network
Managing Editor: Emma Hargreaves
Editors: Ginny Russell, Anne Wilbourn, Julie Hamilton
Graphic Designer: Jane Grainger, Grainger Dunsmore Ltd
The ESRC Genomics Network (EGN) is Cesagen, Egenis and Innogen,
examining numerous aspects of the social and economic significance
of genomics, and the ESRC Genomics Policy and Research Forum
tasked with connecting this research with national policy. The EGN
also includes the ESRC Attitudes to Genomics survey based at the
University of Surrey. 
The ESRC Genomics Network Newsletter is FREE and published twice
a year. To subscribe please contact: gnn@ed.ac.uk
Disclaimer:
The views and opinions expressed in this publication are those of the
contributors and authors of the articles and are not necessarily the
views and opinions of the ESRC Genomics Network. Whilst every effort
has been made to ensure the accuracy of the information provided,
neither EGN nor its employees or agents can be held responsible for
any inaccuracies or omissions in this publication, whether caused by
negligence or otherwise.
Copyright © ESRC Genomics Network
Features
Reconstructing the 1918 
flu virus
What would happen if Avian Flu became 
as lethal as the 1918 ‘Spanish flu’? 4
Trust, benefit sharing and 
human genetic databanking
The ethical, legal and social implications




We ask four contributers what constitutes
good public engagement in the areas of
science and technology 12
Metabolic syndrome
A real condition or just another 
‘Big Pharma’ creation? 20
Are genetic tests special?
Do people think all genetic information 






Have your say 19





                                   
These are good, though changing times for the ESRC’s
Genomics Network (EGN) and for the ESRC Genomics Forum
within it. 
The three Centres that conduct most of the EGN’s research (CESAGen, Egenis and
Innogen) have recently been comprehensively and successfully appraised by the
ESRC’s international review team and are now making detailed plans for their 
second phase of life, starting next calendar year. The Forum, too, is entering a new
phase. Over the past two years, under the direction of Professor Michael Banner,
the Forum has established itself as a central node in the Genomics Network, 
hosting meetings and workshops of interest to the EGN as a whole, and facilitating
and enhancing the links between social scientists, scientists and policy makers.
Now Michael is moving to a new post in Cambridge, and I have had the good 
fortune to be appointed Director in his place. A new Deputy Director is starting too
- Dr Steve Sturdy, seconded from the Science Studies Unit at the University of
Edinburgh - and we have clear ambitions for the next phase of the Forum's 
development.
Firstly we have an organisational ambition: we want to help the Genomics Network
function even more collaboratively. This Newsletter is already an excellent example
of the way that the EGN can carry out co-operative work and publicise its 
achievements. But there are many other opportunities to work together. 
In particular, the Genomics Network is planning to hold its first joint conference in
autumn 2007 and the Forum has volunteered to take the lead in organising this
major meeting – informally known as the 2007 ‘Oktoberfest’.
We also intend to make sure that the focus of Forum work continues to develop.
Our programme of Visiting Fellows is now packed with international scholars and
policy actors and we have appointed new Research Fellows in the Forum, as well.
Additionally, we have recently agreed our contribution to the ESRC’s Social
Science Stem Cell Initiative in developing new seminars and activities focusing on
stem cells in an international context. We are also developing proposals for new
activities relating to the understanding of genetics and social behaviour. 
Our third ambition is to further clarify and celebrate the distinctive contribution of
social science work to the understanding of genomics in a social context. 
For example, virtually everyone is aware that advances in understanding of the
human genome and the genetics of ill health will most likely lead to new policy and
ethical dilemmas. Medical practitioners, politicians and policy-makers commonly
ask how ‘individuals’ will or should respond to these novel situations. 
Social scientists are uneasy with this framing of the question since sociologists,
anthropologists and psychologists are aware that people do not typically make
choices and decisions in such an individualistic fashion. Beliefs about obligations
and duties, estimations of the implications for others (particularly for relations,
friends and colleagues) and even the way that the ‘choice’ is suggested in the first
place all influence the decisions that people take. Personal conduct needs to be
understood through well-designed empirical investigation and not just by asking
oneself what others seem likely to do. This empirical work, in its diverse forms, is
the heart of the Network’s work and a key role for the Forum is to find new ways to
publicise and promote these endeavours.
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Editorial
The editorial in this issue
comes from Steve Yearley,
newly appointed Director of
the ESRC’s Genomics Policy
and Research Forum at the
University of Edinburgh.
Professor Yearley joined the University
of Edinburgh in 2005 after having
served as Head of Department in
Sociology at the University of York
since 1999. He also became a Senior
Professorial Fellow to the Forum at
this time.
Attracted to the intellectual excitement
surrounding post-Kuhnian science
studies, Steve left his natural science
studies behind to explore the social
place of science in modern society.
In particular, he has investigated how
scientific expertise is used and 
challenged within environmental 
disputes and in environmental 
policy-making.
Professor Yearley has written six
books, the most recent of which are
Making Sense of Science:
Understanding the Social Study of
Science (Sage, 2004) and Cultures of
Environmentalism: Empirical Studies in
Environmental Sociology (Palgrave
Macmillan, 2004). He also co-authored
the Sage Dictionary of Sociology
which appeared earlier this year. 
In addition, he has authored and 
co-authored more than 40 articles in
peer-reviewed journals and more than
30 chapters in edited collections.
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This is a frightening proposition – so much so that preparing
for the ‘next pandemic’ has become the focal point of
intense public health activity. Yet, given this vast activity,
there is surprisingly little information on how H5N1 might
mutate to become as lethal as the Spanish flu.  Addressing
this question could help us to understand the current threat
posed by H5N1 as well as guide efforts at drug and vaccine
development, but attempts to answer this question have
proven controversial.
Every time a new human case of H5N1 is reported, the virus
is isolated from the patient and tests are run to check
whether the virus has evolved to better infect humans: it
would be very bad news indeed if the virus were to become
capable of human-to-human transmission.  In order for
scientists to understand the significance of any mutations in
the H5N1 genome, a comparison must be made with the
genetic code of previous human influenza strains thought to
have mutated from avian influenza.  The pandemic influenza
viruses of 1957 and 1968 are not thought to have originated
from avian influenza, but the pandemic of influenza 1918
may have.  Thus scientists have wondered: if the 1918
influenza virus was indeed avian in origin, what can be
learned from studying its genome?
To investigate this, it was necessary to reconstruct the 1918
flu virus genome, as no samples were on record and its
genome was not characterized in 1918.  A research team led
by Jeffrey Taubenberger, of the Armed Forces Institute of
Pathology in Maryland, decided to recreate the virus using
the lung tissue samples of a flu victim buried in Alaska’s   
permafrost. RNA was isolated from the samples, converted
into DNA fragments and then pieced together to yield the
genome, which was subjected to sequence and phylogenet-
ic analysis.1 Another research team subsequently used the
genome sequence to reconstruct the 1918 flu virus.
This was achieved by injecting the DNA into a kidney cell
culture, leading to the production of viral particles that were
used to infect mice and study the pathogenicity of the virus.2
Taubenberger and his team concluded that the 1918 flu virus
was most likely an ‘avian-like’ virus that adapted to humans.
They suggested that ten amino acid changes in viral
polymerase proteins consistently differentiate the 1918 and
other human influenza virus sequences from avian influenza
virus sequences.  Furthermore, they pointed out that
“a number of the same changes have been found in recently
circulating, highly pathogenic H5N1 viruses that have caused
illness and death in humans and are feared to be the precur-
sors of a new influenza pandemic.”1
Worryingly, this suggests that H5N1 is indeed worthy of
considerable attention as it seems to be evolving similarly to
the 1918 flu virus. This interpretation has, however, been
contested.  Upon reviewing Taubenberger’s data, two groups
have argued that although useful for understanding how
influenza viruses adapt to and infect humans, they can also
suggest that the virus evolved in mammals and not in birds.
Consequently, as one group argued, focusing solely on avian
influenza might neglect other potential sources of a human
flu pandemic.  They recommended that “… the current
intense surveillance of influenza viruses should be
broadened to include mammalian sources.”3 The second
group criticized Taubenberger’s research for making too
strong a link between current strains of avian influenza and
the 1918 flu, “By stating that the high pathogenicity of the
1918 virus is related to its emergence as a human-adapted
avian influenza virus, the authors raise the possibility that an 
Scientists have long agonized over influenza
pandemics.  The worldwide spread of H5N1
avian influenza has been dramatized by the
media and exemplified by public health
agencies as a rationale for increased global
co-ordination on infectious disease control.
At the back of many minds is the nagging
question: what would happen if H5N1 became
as lethal as the 1918 ‘Spanish flu’, which killed
up to 50 million people worldwide?
What would happen if H5N1
became as lethal as the 1918
‘Spanish flu’, which killed up to
50 million people worldwide?
Jonathan Suk, on behalf of Innogen
Research Fellow, ESRC Genomics





    
emerging avian strain could resemble the 1918 flu.  This
alarming implication, which is based on misinterpretation of 
phylogenetic data, is completely unjustified and could 
seriously distort the public perception of disease risk, with
grave economic and social consequences.”4
What appears to be at stake in this argument is not only the
correct interpretation of the original source of the 1918 flu
virus, but whether or not current concerns over H5N1 are
over-stated.  Debates of this nature are commonly observed
in issues that involve the calculation of potential risks in 
situations of scientific uncertainty.  In this case, not only is
key information about H5N1 not possible to obtain (e.g. Will
it become transmissible between humans? How? When?),
but some of the available data are open to interpretation.
Despite the resurrection of the 1918 flu virus, it remains
unclear whether H5N1 is an imminent public health disaster
or merely a red herring detracting public health from more
pressing matters.
To be fair, the 1918 flu virus research was not entirely 
intended to answer such difficult questions: the main 
objective has been to obtain a basic understanding of the
virus to eventually facilitate vaccine and drug design.5
Ironically, however, the very fact that this research was 
pursued increases the risk of the ‘next pandemic’, as the
resurrection of the 1918 virus raises two significant 
biosecurity concerns.  First, there is significant concern over
the potential for accidental release of the virus from a 
laboratory.  The work was done in an enhanced biosafety
level-3 lab, the same level from which a SARS virus escaped
in Singapore in 2003 and Beijing in 2004.6 Second, because
the genome sequence is freely available on the internet,
some have argued, “its reconstruction by rogue scientists is
now a real possibility.”6
It remains to be seen whether these biosecurity risks are
greater than the risk of a human H5N1 pandemic.
Either way, preparing for the next pandemic appears to be a 
prudent choice.
References
1 Taubenberger, J.K. et al (2005). Characterization of the 1918 influenza virus
polymerase genes. Nature 437: 889-893.
2 Tumpey, T.M. et al. (2005). Science 310: 77-80.
3 Gibbs, M.J. & Gibbs, A.J. (2006) Was the 1918 pandemic caused  by a bird
flu?.  Nature 440: E8.
4 Antonovics, J., Hood, M.E., & Baker, C.H. (2006) Was the 1918 flu avian in
origin? Nature 440: E9.
5 Von Bubnoff (2005) The 1918 flu virus is resurrected. Nature 437: 794 –795.
6 Van Eken (2006) When risk outweighs benefit. EMBO Reports 7 (Special
Issue): S10-S13.
Focusing solely on avian
influenza might neglect other
potential sources of a human
flu pandemic.
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Human genetic databanks provide the
essential raw materials for many aspects of
modern biomedical research. The term
‘databank’ is broad in scope, incorporating
everything from collections of pathological
samples through to databases of sequence
information and large scale biobanks that link
genetic information derived from tissue
samples with medical records and family
histories. All of these varieties of databanks
are likely to continue to play a pivotal role in
the ongoing endeavour of understanding the
basis of human disease at the genetic level,
and putting that basic knowledge into
practical application. 
Human genetic databanking also raises a number of
profound ethical, legal and social implications. The obligation
to obtain consent is always likely to be of paramount ethical
concern because of the privacy and discrimination issues
raised by the use of identifiable genetic information.
However, the precise nature of the consent requirement is
unclear when tissue and information are stored for future
unspecified research. Alongside this issue of consent to use
for research purposes, there are other equally valid and
growing concerns about the direct commercial use of
databanked material and the more indirect commercial use
of the results of research that has utilised databanked
material. These concerns are inextricably linked to the
consent question, because arguably fully informed consent
requires disclosure of both direct and indirect commercial
dealings with human genetic material and information. 
There have been a number of surveys conducted around the
world attempting to measure the level of public trust in
science in general and in biomedical science in particular.
Although a UK Parliamentary inquiry reported that there was
a ‘crisis in trust’, other evidence indicates that trust in
publicly funded research remains high. However, the
evidence also suggests that the level of trust decreases
significantly when there is industry involvement. For exam-
ple, one Australian study has suggested that public trust in
stem cell researchers is linked to their perceived motivations:
publicly funded researchers are seen to be motivated more
by benevolence and less by self interest than private sector
researchers. 
One aspect of the public trust problem is that private
companies are perceived as making huge profits from the
exploitation of patented inventions developed using tissue
and information that has been freely donated (although for
the companies themselves the risks are high and such
rewards are not always forthcoming). This problem is likely
to be exacerbated in the area of human genetic databanking
if the managers of the databanks and the researchers using 
the databanked materials and information become involved
in the commercialisation processes. There is evidence of
increasing commercialisation of both the storage and the
research phase, even where they are conducted in publicly
funded institutions. The usual justification for this is that
industry involvement is necessary to boost public funding
and to ensure that research results are actually translated
into new developments in healthcare. In return, the industry 







Dr Dianne Nicol 
Centre for Law and Genetics 
University of Tasmania
ESRC Genomics Forum Visiting Research Fellow, May-June 2006
       
One Australian study has 
suggested that public trust in
stem cell researchers is linked
to their perceived motivations:
publicly funded researchers are
seen to be motivated more by
benevolence and less by self
interest than private sector
researchers. 
temporary periods of market exclusivity, during which time
the patent owner can recover research costs (and, they
would surely hope, make some profits) by having control
over who makes, uses and sells the patented invention.
This all makes good sense in theory: researchers get to do
their research, investment by industry is protected and the
public interest is served because new healthcare products
are developed. However, the people who are supplying the
essential raw materials for this research seem to be left out
of the loop and it is not difficult to see why they may feel
somewhat marginalised, and even exploited. 
Why, then, do people continue to participate in this type of
research? It is widely recognized that people generally
participate for purely altruistic reasons, because of the likely
benefit that such research brings to society as a whole.
They may also have other personal reasons for participating,
for example if they or their families suffer from a particular
medical condition, which they believe may be alleviated as a
result of the research. Although some research participants
are paid for their participation (for example, in some clinical
trials), as a general rule payment is rarely considered to be a
serious option, because of long-standing concerns about the
commodification of human tissue. In the increasingly
commercialised research environment, where everyone but
the research participants appears to have a financial interest,
the altruistic model of participation is under serious threat.
How can these concerns be alleviated? 
Whilst some would argue that the solution is to pay
participants a fair price for using their material, this view is
not widely supported. On the contrary, in addition to the         
potential for this to impact on the cost of doing biomedical 
research, there is concern that it could lead to coercion to
participate. In the alternative, benefit sharing is being
mooted both as an ethically appropriate means of balancing
the conflicting interests involved in genetic databanking and
also as potential solution to the problem of loss of
public trust. 
It could be argued that the promise of new healthcare
developments is sufficient to satisfy any obligation to provide
benefits to participants in biomedical research. But if benefit
sharing is a desirable end in this area of human genetic
databanking then it must be addressed in a genuine way.
If researchers and databank operators try to satisfy
obligations to provide for benefit sharing by means of trite
statements of future possibilities, then rather than promoting
trust, they could further erode it. This is not to say that the
only benefit that should be considered is financial benefit.
The umbrella of benefit sharing could also include more
indirect benefits, such as preferential access to new
healthcare developments, as well as genuine efforts to fully
disclose all relevant information, particularly information
about the process of commercialisation, and to explicitly
recognise the input that participants have made. 
The need to address benefit sharing in human genetic
databanking has been discussed for some time in the
academic literature and at the international policy level.
However, the incorporation of such considerations into
actual databanking policies has been slow, although some
models are emerging. For example, a report by the
Newfoundland and Labrador Department of Health and
Community Services has recommended that benefit sharing
arrangements should be required for any human genetic
research with commercial potential and that the provincial
government should play a central role in negotiating suitable
arrangements. 
It is unlikely that there will be one single model for benefit
sharing in all circumstance. But now is the time for all parties
engaged in databanking to seriously consider how to
implement appropriate benefit sharing arrangements.
They should not see benefit sharing as a threat to the
commercial success of the endeavour but as an important




A more detailed analysis of these issues is presented in Dianne Nicol ‘Public
Trust, Intellectual Property and Human Genetic Databanks: the Need to Take
Benefit Sharing Seriously’ (2006) 3 Journal of International Biotechnology Law
89-103
Dr Nicol is a member of the Centre for Law and Genetics (CLG), a cross 
institutional research group with members from the University of Tasmania and
Melbourne University. The CLG receives funding from the Australian Research
Council for a series of projects examining legal and ethical issues associated
with genetics and biotechnology in Australia, particularly focusing on 
commercialisation. The CLG is currently working on a five year project on the
regulation of human genetic databanking in Australia, funded to the end 
of 2009.
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In the increasingly 
commercialised research 
environment, where everyone
but the research participants
appears to have a financial
interest, the altruistic model of
participation is under serious
threat. How can these concerns
be alleviated? 
       
Egenis relocates to Byrne House
A delightful but formerly dilapidated Regency residence on
the Streatham Campus at Exeter University has become the
new home of Egenis. The building was restored with the
specific needs of Egenis in mind, making it the ideal location
for future activities. The renovation was made possible by a
donation from Dr Patrick Byrne, President and Chairman of
Utah-based internet retailer, Overstock.com Inc; and the
restored building, formerly known as Montefiore, has been
renamed Byrne House.
ESRC Genomics Forum inaugural Artist
in Residence
The Forum is delighted to announce the appointment of
visual artist, Alistair Gentry, to work with us in developing an
imaginative and experimental arts project based on the
relationship between genomics and society. His 6 month
residency will include a public engagement programme of
talks, events and salons, in association with the University of
Edinburgh’s Talbot Rice Gallery.
Alistair, who is the Forum’s first artist in residence, is a ‘free
range’ writer and artist with a diverse resume. His work has
been seen and heard in digital media, on radio, television
and the stage, in art galleries, in print and on the net.
He’s the author of two published novels Their Heads Are
Anonymous and Monkey Boys and— with Joe Magee—
made the frequently (and globally) shown digital animation
Hypnomart for Channel 4 Television. 
You can follow Alistair’s residency through
www.genomicsforum.ed.ac.uk 
ESRC funding for CESAGen
CESAGen Professorial Fellow, Professor Peter Glasner, has
been awarded funding by the ESRC to carry out a follow-up
study of human tissue engineering. The two-year study,
which began in April, is entitled Regulatory Innovation of a
Contested Technology Zone:  Follow-Up Study of Human
Tissue Engineering in the UK and EU. The project also
involves Dr David FitzPatrick of University College Dublin
and Dr Alex Faulkner of Cardiff Institute of Society, Health
and Ethics (CISHE) who is the Principal Investigator.
New tissue banking regulation is currently being
implemented in Europe and the UK. This study examines the
legislation process and content. Fieldwork will be
undertaken in regulatory fora and key informants will be
interviewed. The project will contribute to understanding of
healthcare system innovation, Europeanisation, technology
zones, and public policy process in conditions of
globalisation.
Letter on human enhancement published
in New Scientist
Dr Paula Boddington, from CESAGen Cardiff, had a letter on
human enhancement published in New Scientist in June.
The letter was in reply to one by Mark Bruce, who was
arguing that no one mourns the passing of homo erectus, so
likewise we should not mourn the passing of homo sapiens
for something better. Paula, who works on a CESAGen
project funded by the Wellcome Trust The Transgenerational
Communication of Genetic Information, argues for a more
critical look at human enhancement suggesting that the
values underlying current enhancement projects need to be
thoroughly examined, and that a genuine wish to 'enhance'
humanity would include addressing the vast amount of
human potential currently wasted by economic and social
deprivation. To read the letter visit the New Scientist website
at www.newscientist.com/article/mg19025571.200.html.
New international summer school
a big success
CESAGen researchers and post graduates took part in an
inaugural international summer school in Amsterdam in
June. The summer school, entitled The Genome Society:
ELSA Genomics, the State of the Art and Beyond, was
organised by the Dutch Centre for Society and Genomics
(CSG) and the International School for Humanities and
Social Sciences, University of Amsterdam. The purpose of 
Byrne House
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the school was to explore the status of research into the
ethical, legal and social aspects (ELSA) of genetics,
the  merits of ELSA genomics research and its proclaimed
societal engagement, both in decision making and in public
interaction.  Experts from Lancaster, Harvard, Amsterdam,
Maastricht and Vienna gave presentations to participants
which included researchers from elsewhere in the UK, the
Netherlands and US. It is hoped that this will become an
annual event.
Social study of systems biology
Egenis researcher Dr Jane Calvert was awarded an
ESRC/SSRC Collaborative Visiting Fellowship to travel to the
US in July 2006 to study the social dimensions of systems
biology - arguably the successor science to genomics.
She spent the first half of her visit conducting interviews and
observations at the Institute for Systems Biology in Seattle
and the remainder of the time analysing the data with Prof
Joan Fujimura from the University of Wisconsin-Madison.
Systems biology is an emerging field and the UK has
recently invested nearly £50 million into its development. 
So far there has been little sociological analysis of the field,
but its interdisciplinary zeal, methodological approach and
philosophical assumptions make it a fascinating area 
of study.
Innogen research influences world leaders
at G8 Conference
Innogen’s work on the Detection and Identification of
Infectious Diseases Programme for the Office of Science and
Technology informed G8 negotiations on infectious diseases. 
The Office of Science and Technology Report 'Infectious
Diseases: preparing for the future', now available through the
Foresight website www.foresight.gov.uk, was instrumental in
the issue of a G8 paper on the official website of the Russian
Presidency www.en.g8russia.ru/docs/10.html.  
'Infectious Diseases: preparing for the future' is the latest
report from Foresight, a Government science-based
programme, led by Sir David King, the Government's Chief
Scientific Adviser.
The project looked at the evolving risk and the changing
requirements for detection, identification and monitoring of
infectious diseases in plants, animals and humans.
It concludes that current and new infectious diseases will
continue to have profound human, economic and social
impacts, and that unless new ways of sharing research and
technological advances are implemented at all levels, the
poorest people in the world will continue to suffer dispropor-
tionately. The report includes key findings, a comprehensive
action plan, and case studies illustrating the potential 
benefits of new technologies on future disease outbreaks.
Forum welcomes Chinese scientists
Earlier this year, the ESRC Genomics Forum, welcomed a
high powered delegation of Chinese natural and social
scientists to Edinburgh to discuss the issues and impacts of
modern life sciences in China and the UK.
Representing a number of Chinese institutions, including
Peking University, the Chinese Academy of Social Sciences,
Chinese Academy of Medical Sciences, Beijing Institute of
Transfusion Medicine, Shanghai Institutes for Biological
Sciences and the National Natural Science Foundation, the
11 international visitors were joined by UK delegates from
the London School of Economics (LSE), University of
Newcastle’s Policy, Ethics and Life Sciences Research
Centre (PEALS), BIOS, Genewatch, the University of
Edinburgh and the ESRC Genomics Network.
During the 2 day meeting, participants discussed a range of
social, economic, policy, ethical and scientific issues such as
the economic benefits of modern life sciences research;
types of genetic services available in the UK and China and
their social consequences; and public awareness and
knowledge of scientific issues.
Amsterdam
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New ‘criminal’ genes project
Work has begun on a new project headed by CESAGen
Deputy Director, Dr Mairi Levitt, looking at the policy
implications of genetic factors in criminal behaviour for the
criminal justice system. The research team is Elisa Pieri and
Dr Neil Manson from The Institute for Philosophy and Public
Policy, Lancaster University. The project ‘Criminal’ Genes
and Public Policy focuses on the ethical and social issues
raised by collection and storage of genetic information
including issues of justice and equality in the use of genetic
information and allocation of services. Stakeholder groups
will be given the opportunity to consider possible implica-
tions of the research for their professional work. This focus
group research will be supplemented by interviews with key
policy experts working in the field.
Is a gene revolution around the corner?
For several years Egenis has enjoyed frequent co-operation
with the Centre for Society and Genomics in the
Netherlands, and the relationship has again proved fruitful.
Egenis Co-director Professor Steve Hughes will be acting as
an informant to answer the question ‘is a gene revolution
around the corner?’ Professor Hughes has worked with the
Dutch centre on a successful bid to launch a project which
focuses on rice genomics. The project aims to interact with
several researchers and practitioners in genome based rice
improvement, in order to understand how to overcome
previous limitations. Researchers will be based in West
Africa, the UK and the Netherlands. The project aims to
examine strategies that work towards providing food security
in the developing world. 
Innogen Director invited to speak at the 
World Knowledge Forum
The theme of this World Knowledge forum to be held from
17th-19th Oct in Seoul, Korea is ‘Creative Economy’. 
The creative economy is based on the knowledge and ideas
that society’s intellectual capital generate to produce 
concepts that drive invention and innovation. We need such
breakthroughs to tackle problems such as poverty, conflict
and disease. Specifically this meeting will focus on the
Digital Society, Growth, Finance, Brand and Asia. Reflecting
the wider world, Asian countries can either improve or retard
their social, political and economic evolution. 
www.wkforum.org.
Egenis students present research in
Washington DC
Three Egenis PhD students, Bonnie Green, Mario Moroso,
and Maren Klotz, travelled to the Science & Technology in
Society Conference in Washington DC to give presentations 
about their research. This interdisciplinary graduate student
meeting was hosted at the headquarters of the American 
Association of the Advancement of Science. Bonnie Green
gave a paper on conceptualisations of genetic technologies
as activities instead of artefacts. Mario Moroso presented his
research into the beginning of the GM controversy in Britain,
and Maren Klotz discussed the changing collective images
of kinship which British policy makers drew on during
reproductive technology regulation.
Consequences, opportunities and challenges
of modern biotechnology for Europe Project
Innogen will be contributing to a European team of
researchers providing advice for members of the European
Parliament through ETEPS (a network for European Techno-
Economic Policy Support). The objective of the project is to
provide an assessment of the consequences, opportunities
and challenges that applications of modern biotechnology
present for the EU, to identify and quantify the contributions
of modern biotechnology to the achievement of major
European policy objectives as formulated in the Lisbon
Agenda and the sustainable development strategy. Innogen's
contribution will be in mapping the adoption of modern
biotechnology in primary production/agro-food in the EU and
evaluating the consequences, opportunities and challenges
of applications in primary production and agro-food.
Edinburgh International Book Festival 
The ESRC Genomics Forum supported a series of events
examining social and ethical aspects of genomics research
at this year's Edinburgh International Book Festival. In three
separate discussions, titled ‘Embryos and Ethics’, leading
expert on medical ethics Professor Sheila McLean and
renowned broadcaster, Joan Bakewell, discussed the huge
advances in genetic and reproductive science and what they
mean for families; Professor Ian Wilmut and former Bishop of
Edinburgh, Richard Holloway, journeyed to the heart of
questions posed by scientific advances; and leading science
fiction writers Ken MacLeod and Charles Stross, looked at
whether the use of science in fiction helps the public
understand some of the concepts and advances in the 
ever-changing scientific field. 
News
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Egenis project on claims-making in
Nutrigenomics
Egenis senior research fellow Dr Paula Saukko has been
awarded a Wellcome Trust grant to study claims-making in
nutrigenomics. The project will investigate discourses on the
interaction between nutrition and genomic variation in
scientific, popular and public health media and in marketing
of commercial nutrigenomic screens. The project aims to
provide a baseline analysis of information provided to the
public on nutrigenomics in order to contribute to policy-
discussions on regulating information about genetic tests.
Other members of the research team are Professor Steve
Hughes from Egenis and Professor David Melzer and
Professor Nicky Britten from Peninsula Medical School.
A research fellow will start on this project in Egenis in the
autumn of 2006.
www.centres.ex.ac.uk/egenis/research/nutrigenomics
Taxonomy at a crossroads: science, publics
and policy in biodiversity
A team of sociologists and anthropologists from CESAGen
and the Sociology Department at Lancaster University
(Brian Wynne, Claire Waterton and Rebecca Ellis), in
collaboration with the Natural History Museum in London,
the Biodiversity Institute of Ontario and the Smithsonian
Institution, are about to embark on a 3 year ESRC funded
project which will explore contemporary innovations in
taxonomy. We are currently witnessing rapid changes in the
ways in which natural organisms are identified and
classified. Conventional forms of taxonomy (using whole
organisms)  are now working side by side with molecular and
barcoding techniques using DNA segments. These are excit-
ing times for the taxonomic and biodiversity science com-
munities. A social scientific insight is however welcomed by
them as they grapple with technological and social
unknowns. One of the aims of the research is to work
together with  natural scientists to reflect on ways in which
these innovations might influence the future of taxonomy
and biodiversity science in general. The research will also
link with one of CESAGen’s Flagship Projects Indigenous
Peoples and Globalisation of Genomics in Amazonia by
exploring issues around intellectual property and plant and
animal genomics.
The Philosophical and Social Dimensions of
Microbiology Workshop
Egenis has hosted an international workshop on The
Philosophical and Social Dimensions of Microbiology.
Participants came from a variety of disciplines including
microbiology itself. A special issue of Studies in History and
Philosophy of Biological and Biomedical Sciences, based on
the papers presented at the Workshop, will be published in
2007. Further discussion of microbiological issues and
planning for other meetings and publications will take place
in July 2007 at Exeter during the meeting of the International
Society for Historical, Philosophical and Social Studies of
Biology. Egenis will continue to host a Dimensions of
Microbiology webpage. It will cover philosophical, historical,
scientific and sociological dimensions of microbiology, with a
special focus on meetings and opportunities for
collaboration between like-minded researchers.
www.centres.ex.ac.uk/egenis/microbiology/index 
New PFGS journal launched
Researchers from CESAGen (Dr Mina Bhardwaj) and the
ESRC Genomics Forum (Dr Alessandro Rosiello) form part of
the editorial board of a new online journal published by the
Postgraduate Forum on Genetics and Society (PFGS).
The new journal entitled Journal of Ethics, Life Sciences and
Society (JELS) is a free access, peer reviewed, interdiscipli-
nary publication with the remit of providing a platform for
postgraduates to publish their doctoral work/work-in-
progress on subjects related to ethics, life sciences and
society. It will be published bi-annually. For more information
visit the PFGS website at www.pfgs.org.
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Dr Mairi Levitt
Deputy Director of CESAGen
There is widespread agreement among social scientists,
funding bodies and governmental organisations about what
constitutes good public engagement in the areas of science
and technology.  Firstly, public engagement should be
upstream, taking place at an early stage before research, or
technological applications, are underway.  This gives the
public (or publics) an opportunity to contribute to the
direction and flow of research and technology or even to
dam the stream. Secondly, it should have an open-ended
agenda, rather than being managed by experts.  Thirdly, it
has a deliberative element with active participants and the
potential to shape science policy.  Finally, there are positive
reasons to engage the public and benefit from their
expertise, in particular, publics bring their own social
experiences to bear on science and technology.
A common finding from public engagement exercises is that
people have an interest in how an application of technology
will work in practice and how it will impact on other parts of
society.  This is just the sort of forward thinking that tends
not to have been done in relation to technology from private
cars and cheap airfares to mobile ’phones.  The public see
science as firmly rooted in society and typically raise
questions about the science itself (who funds this research 
and why? what are the alternatives?), its application 
(who will benefit? how will this work in practice, who will be
responsible? how will it be regulated/controlled?) and the
long term effects (what sort of society might this bring
about? is this what we want?). The science and technology
is not seen as neutral, above or separate from politics and 
culture, but as part of society.  
Upstream public engagement is carried out with focus
groups, citizen’s juries and consensus conferences among
other methods, or using theatre or a games format.
Scientific researchers are also encouraged by their funding
councils to become involved in communicating their
research to the public.  Imaginative methods are used 
including hands-on workshops, interactive exhibitions,
drama and comic books. A popular activity for young people
is to learn about the techniques of forensic science through
a workshop or murder mystery day. Children collect
evidence and use a range of scientific techniques to gather
clues and find the culprit.  There seems to be a gap between
these activities (often called ‘public engagement’) and the
model of public engagement to which the funding bodies
subscribe in their policy statements. In the ‘hands-on’
activities the aims are to make science exciting, to enthuse
young people and the general public about science and to
develop scientists’ communication skills. However, it is the
model of science underlying many of these activities that is
at odds with that implicit in upstream public engagement.
In one model science gives the correct answer, solves the
crime or puzzle, it provides objective facts.  In the other,
science is inextricably bound up with its social and political
context.  The way DNA technology is used in crime control
in UK raises questions about the shaping of technologies by
social and political context, the uncertainties of science and
the ways scientific evidence is presented and understood in
court.  Young people may be more enthused by science
when, as in some of the activities, the complexities are not
ironed out.  In public engagement work young people, like
adults, question the science (will this work like they say it
does? why do this when there are more important things?)
If the public are not engaged with the process by which
scientific facts are produced in the particular historical and
social context of real research, then it is not surprising if
mistrust of science is engendered when those facts turn out
to be less than solid.  
If the public are not engaged
with the process by which
scientific facts are produced in
the particular historical and
social context of real research,
then it is not surprising if  
mistrust of science is 
engendered when those facts




‘Public engagement’ is a buzz phrase for
many scientific research institutions,
practitioners and funders. But what actually is
public engagement? Why is it important?
How can it be done well? We offer 4
perspectives from the ESRC Genomics
Network that try to answer these questions.
PERSPECTIVES ON
       
Dr Matthew Harvey 
Research Fellow
The ESRC Genomics Forum
Reasons why there is, or should be, public engagement
range from the romantic to the cynical. Toward the latter,
engagement could be understood as an attempt to manage
public opinion, or to restore order following highly visible
public and expert dispute over GM crops, the control of foot
and mouth disease, the MMR vaccine and so on.
Toward the former, engagement could be understood as part
of a political movement concerned with science governance
becoming more democratic.  Engagement this time would
not be to restore the old order, but to establish a new one.
This democratic thrust underpins much social scientific work
in the area, and social science has helped push forward the
very idea of public participation.
First, ‘The Public’ became defined as those excluded and
alienated from decision-making culture, which was/is
dominated by collusion between policy-makers and
technical experts.  Then social science set about trying to
come between scientific and political institutions, pointing to
the risky consequences of science and technology, and to
the undemocratic character of decision-making.  It even,
most notably in the sociology of scientific knowledge,
undermined the main qualities by which science and
technical expertise became tools for policy-making in the
first place - objectivity, disinterestedness, and universalism.
Finally, highlighting the social, ethical and political faces of
science, social science reimagined the governance of
science and technology, moving public engagement and
public knowledge upstream to shape the way science relates
to decision-making, and the trajectory of scientific
development.
This model is strongly democratic and begins by granting
rights to various publics – citizens, marginalised groups,
stakeholders and so on – to be involved in policy and
decision making. The frames, concepts and issues these
groups hold, then help establish the terms of reference for
the decision.  This rearrangement is founded on a
proceduralist understanding of democracy: that is, the
outcomes of deliberation are legitimate if they are the
product of a certain ideal procedure.  
Yet, whilst the democratic shortfall and narrow technical
focus of current procedures has been exposed, does the
new engagement model offer improved tools to manage
science?  Almost, but not quite.  Certainly, technical aspects
cannot determine any decision, which must take into
account the social and moral dimensions of science and
technology.  However, appeals to the democratic rightness
of  public involvement leaves the precise grounds and terms
of engagement under-developed.  The problem has become
focused on the relationship between the public on the one
hand, and science, scientists and policymakers on the other.
For example, the latest Eurobarometer on biotechnology
presented citizens a stark choice: ‘should decision-making
be left primarily to the experts or based mainly on the views
of the public?’. 1 Some 59% thought the former, but talking
in these terms shifts attention away from the particulars of
any policy or decision and its epistemic dimensions.
In the push toward engagement, it is not always clear to
policy-makers, scientists, industry and maybe even citizens
why ‘The Public’ should be intrinsically involved and what
they might add.  Under these conditions, engagement is
likely to remain tokenistic.  This situation could be avoided
by  emphasising and championing the particular capacities,
capabilities and contributions of different publics whoever
they are, whatever their social location (mother, scientist,
farmer, citizen, ‘x’) according to the particular policy in
question; in short, by drawing on their expertise as much as
their rights. This keeps in mind that there is a policy or
decision to be made and something substantive to discuss.
The difficulty, now, is not showing the need for more
inclusive and engaged procedures, but in developing new
decision-making institutions that are democratically robust,
yet which respect a division of labour. 2
References
1 Gaskell, G, et al. 2006, Eurobarometer 64.3,
http://www.ec.europa.eu/research
2 See for example Collins, H., Evans, R., 2002. Social Studies of Science,
32 (2):235-296.
In the push toward
engagement, it is not always
clear to policy-makers,
scientists, industry and maybe
even citizens why ‘The Public’
should be intrinsically involved
and what they might add.  
13Genomics NETWORK ISSUE 4 October 06
Feature Article
N
           
14 Genomics NETWORK ISSUE 4 October 06
Sarah Cunningham-Burley,
Gill Haddow, Sarah Parry 
Innogen
As social scientists with an interest in scientific and medical
technologies we are increasingly called upon to join 
interdisciplinary teams at the ‘cutting edge’ of scientific
developments partly because some scientists and policy
makers want to be perceived as sensitive to public concerns
and transparent about their research. At the same time, this
position is partly of our own making as the critiques of 
public understanding of science become increasingly 
mainstream and reflected back to us in the discourses of
scientific governance, e.g., policy statements, calls for 
funding in the area and in scientists’ own accounts of their
work that increasingly take the public/science interface more
seriously. 
We are also nurturing collaborative relationships for our own
research purposes, getting closer to our subject matter 
(science, scientists and ‘publics’) while pursuing a normative
agenda around public engagement (PE) which seeks to
involve a broader range of interests in discussions and 
decisions about science. However, the impetus for 
collaboration and the inclusion of social scientists in science
projects and scientists in social science projects may come
from different directions. The seemingly symmetrical 
motivations between these two groups around shared 
agendas can mask very different expectations about roles,
perspectives and outcomes.  
Our experience at Innogen includes two collaborative 
projects (Public Engagement on Stem Cell Research &
Public Consultation of Generation Scotland) that bring such
tensions and challenges to light, requiring us, as well as our
collaborators, in biomedical sciences, to be reflexive, 
communicative, cooperative and explicit about our practices.
We have found that our collaborators in science and clinical
medicine are keenly interested in the contribution our 
discipline can make and allow us to subject them to a 
sociological gaze with little or no interference. Collaboration
has also allowed us to clarify the possibilities of participatory
approaches to science, technology and medicine, identifying
routes for change and specifying which areas are up for
negotiation and which are not. Working closely with 
scientists and clinicians also creates opportunities for 
micro-level changes to scientists’ views and practices by
allowing for a deeper and ongoing set of conversations
about our respective research. Linked to this is the potential
for macro-changes to structures and institutional cultures
that may emerge from the application of such understanding
beyond the specific projects themselves. Furthermore, our
social science research that seeks to involve public groups
also affords opportunities for identifying practices and 
mechanisms that promote active citizenship of all involved,
including ourselves and the scientists with whom we work.
In this respect, it is important to engage with ‘scientists as
citizens’ rather than homogenising ‘a scientific’ perspective.
Our experience has shown how scientists operate with a
version of the social and political context of their work that
affords a basis for further disruption of simplistic distinctions
between science/society and scientists/publics.  
Hence, dialogue between scientists, social scientists and
publics can inform the construction and expression of
expertise, experience and legitimacy - issues that continue
to shape theoretical developments in science and 
technology studies.
The establishment of collaborative research projects serves
to structure both cooperation and contestation between
those involved. As both catalysts for, and actors within PE
we are trying to forge a path towards a democratisation of
science (‘walking the walk’) whilst perhaps being in some
danger of cooption (‘talking the talk’). There are sufficient 
critiques to suggest it is an uneasy time for social scientists,
requiring further analysis of the rhetoric and discourse of PE
and associated activities.  While we continue to retain some
scepticism towards the ‘participatory turn’ we remain ever
hopeful that this may lead to a greater public involvement
and interest in the social shaping of science.
Dialogue between scientists,
social scientists and publics
can inform the construction
and expression of expertise,
experience and legitimacy -
issues that continue to shape
theoretical developments in 
science and technology studies.
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Mario Moroso 
Egenis
Since the early 1990s, many people have called for
increased public engagement in science and technology
policy, but what they actually mean often varies significantly
according to the institutions and social groups they belong
to. Social scientists, for example, tend to look at the public
engagement approach as an alternative to the traditional
Public Understanding of Science movement, according to
which scientific illiteracy is the cause of negative attitudes
towards science and technology. Increased efforts in
communication would improve public understanding of
technical issues together with public support towards new
technologies. There is, clearly, a conception of the public as
a uniform mass that is involved in a scientists-to-public
communication process that tends to be pedagogic and
paternalistic.
The alternative public engagement instead, suggests that the
traditional communication campaigns should always, when
possible, be combined with practices that allow the public to
play an active role in the development of science and
technology. Consensus conferences and focus groups are
just two of the possible instruments available for receiving
input from the public. But there is at least one other,
significantly different, idea of public engagement that
appears to be quite widespread among experts and
scientists. In this case, public engagement is an
improvement, rather than an alternative to the Public
Understanding of Science. One of the grounding
assumptions behind this kind of public engagement
approach is that the public do not trust science and
technology as they used to because of the unbridgeable gap
of knowledge between experts and non experts as a result
of the extreme specialisation of contemporary western 
societies. Therefore, while many social scientists tend to 
minimise the theoretical importance of technical and 
scientific ignorance by considering relevant other forms of
expertise and knowledge, some scientists and technologists
tend to keep and actually expand their focus on ignorance.
Ignorance becomes a permanent condition requiring a new
form of communication in order to rebuild trust and therefore
public support. It is not simply a matter of communicating
more, but also of communicating better – better meaning
making science and scientists appear appealing, reliable and
essential with the help of the language developed by 
marketing. There is a strong temptation to rebuild trust and
public support using a policy which explicitly focuses on
appearance. In his Reith Lectures of 2005, Lord Alec Broers
- a highly regarded representative of the scientific 
community - reveals the actuality of this attitude:
"[…] because of the gap in understanding that has 
developed, it may be beyond the grasp of many social 
people to realise that the solutions to the problems created
by technology will themselves be technological. What we
engineers have to do is to be seen to have codes of 
acceptable behaviour and to be living up to those 
standards."
Mistrust of science, therefore, could be not only a matter of
scientific facts turning out to be less than solid, as rightly
pointed out by Mairi Levitt, but also a matter of scientists
being less than confident in their role in society and relying
on a new language for scientific communication that sounds
too commercial to be trustworthy.
There is a strong temptation to
rebuild trust and public support
using a policy which explicitly
focuses on appearance.“
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October 2006
SEMINAR - 2 October 2006
Genetics and responsibility? 
Speaker: Dr Garrath Williams, Institute for Environment,
Philosophy and Public Policy, University of Lancaster.
Organised by Innogen
Venue: University of Edinburgh
www.innogen.ac.uk
SEMINAR - 4 October 2006
The governance of biobanks: recent developments in 
comparative perspective.





PUBLIC LECTURE - 5 October 2006
The Race Myth: More Sincere Fictions in 
the Age of Genomics
Speaker: Dr Joseph Graves Jr, 
North Carolina State University
Organised by ESRC Genomics Forum 
Venue: University of Edinburgh
www.genomicsforum.ac.uk
WORKSHOP - 6 October 2006
Workshop by Dr Joseph Graves
Organised by ESRC Genomics Forum 
Venue: University of Edinburgh
www.genomicsforum.ac.uk
SEMINAR - 10 October 2006
Speaker: Professor Keith Benson, 
University of British Columbia
Organized by Egenis. 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
SEMINAR - 16 October 2006
Why are biological objects so hard to define?  
Speaker: Professor John Dupré
Organised by ESRC Genomics Forum/ Innogen 
Venue: University of Edinburgh
www.genomicsforum.ac.uk
SHORT COURSE - 18-20 October 2006
Genomics and Society: Exploring the Social 
Consequences of Genomics 
Organised by ESRC Genomics Forum 
Venue: University of Edinburgh
www.genomicsforum.ac.uk
WORKSHOP - 18 October 2006
European Research Area on Societal Aspects of
Genomics
Organised by ESRC Genomics Forum 
Venue: London
www.genomicsforum.ac.uk
SEMINAR - 18 October 2006
‘Holding the line’: the symbolic maintenance of the 
modernist categories of nation and boundary in the UK
press coverage of GM crops




SEMINAR - 24 October 2006
Speaker: Hannah Farrimond, Egenis Research Fellow
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
INTERNATIONAL 
CONFERENCE - 25-27 October 2006
The Institutionalisation of Ethics in Science Policy:
Practices and Impact (INES) dissemination conference
Organised by Cesagen 
Venue: Brussels
www.cesagen.lancs.ac.uk
SEMINAR - 31 October 2006
Speaker: Dr Jane Calvert, Egenis Research Fellow
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
November 2006
SEMINAR - 6 November 2006
UK DonorLink Register Two Years on - Using DNA to link
adults genetically related through donor conception
Speakers: Marilyn Crawshaw and Lyndsey Marshall, 
UK Donorlink
Organised by Innogen
Venue: University of Edinburgh
www.innogen.ac.uk
SEMINAR - 7 November 2006 
Bioethics, patenting and the governance of human
embryonic stem cell science: the European case. 
Speaker: Professor Brian Salter, University of East Anglia
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
WORKSHOP - 13-14 November 2007
Genomics and Biosecurity
Organised by ESRC Genomics Forum 
Venue: University of Edinburgh
www.genomicsforum.ac.uk
SEMINAR - 14 November 2006
Speaker: Professor David Papineau, Professor of
Philosophy of Science
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
Events
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SEMINAR - 21 November 2006
Speaker: Bonnie Green, Egenis Centre PhD Student
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
WORKSHOP - 24-25 November 2006
Critical Social Science on the Biosciences
Organised by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/criticalsocialscience
SEMINAR - 28 November 2006 
Speaker: Professor John Dupré, Egenis Director
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
December 2006
SEMINAR - 5th December 2006
Speaker: Professor John Dupré, Egenis Director
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7  
www.centres.ex.ac.uk/egenis/events/seminars.php
WORKSHOP - December 11-14  2006
Heredity in the Century of the Gene. (A Cultural History
of Heredity IV.)
Organised by Egenis/ the Max-Planck-Institute for the
History of Science, Berlin 
Venue: The University of Exeter 
www.centres.ex.ac.uk/egenis/events/culturalhistory
2007
SEMINAR - 16 January 2007
Speaker: Dr Ian M Frayling, Director, All-Wales Genetics
Laboratory Service and Consultant, TBC.
Organized by Egenis 
Venue: Pennisular Medical School, University of Exeter  
www.centres.ex.ac.uk/egenis/events/seminars.php
WORKSHOP - 23-25 January 2007
Training workshop on national and international 
regulation of stem cell science
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
c.hauskeller@ex.ac.uk
INTERNATIONAL
CONFERENCE - 25-27 January 2007
Governing Genomics
Organised by Egenis
Venue: University of Exeter
www.exeter.ac.uk/egenis/governinggenomics
SEMINAR - 20 February 2007
Speaker: Dr Graciela Nowenstein, Egenis Research
Fellow
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
SEMINAR - 27 February 2007 
'Thick' and 'Thin' Reflections on Science, Human Cloning
and Other Matters: Views from British Science
Journalists and Interest Groups 
Speaker: Dr Monica Bonaccorso, Department of Social
Anthropology, University of Cambridge
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
SEMINAR - 13 March 2007 
Green revolutions - past, present and future: whom does
plant-breeding serve?  
Speaker: Professor Jonathan Harwood, Professor of
History of Science & Technology, University of
Manchester
Organized by Egenis 
Venue: Byrne House, University of Exeter, GF7 
www.centres.ex.ac.uk/egenis/events/seminars.php
PUBLIC LECTURE - 20 March 2007
Inaugural Lecture by Professor Steve Yearley 
Organised by ESRC Genomics Forum 
Venue: University of Edinburgh
www.genomicsforum.ac.uk
INTERNATIONAL
CONFERENCE - 26-28 March 2007
Genomics and Society: Retrospects and Prospects
Organised by Cesagen 
Venue: The Royal Society, London
www.cesagen.lancs.ac.uk
PUBLIC LECTURE - 2-15 April 2007
New Drugs, New Benefits - The future of 
biopharmaceuticals 
Organised by Innogen 
Venue: Edinburgh International Science Festival
www.innogen.ac.uk
PUBLIC LECTURE - 2-15 April 2007
Biomedicine or Bioweapon? Biology and Biosecurity in
the post-9/11 world
Organised by ESRC Genomics Forum 
Venue: Edinburgh International Science Festival
www.genomicsforum.ac.uk
CPD Course - 25-27 April 2007
Life Science Companies: Managing a Turbulent Future
Organised by Innogen
Venue: University of Edinburgh 
www.innogen.ac.uk
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New appointments for the ESRC
Genomics Forum 
The Forum is delighted to announce several new staff
appointments this autumn. As well as welcoming Professor
Steve Yearley (see editorial) as our new Director, Dr Steve
Sturdy joins us as Deputy Director, Clare de Mowbray as
Senior Projects and Events Officer (maternity cover), and
Jaymie Myers is our new Senior Secretary. For further 
information about our new recruits, visit: 
www.genomicsforum.ac.uk/aboutus
New Associate Director for CESAGen
Following Director Ruth Chadwick’s move to Cardiff
University, CESAGen has appointed Professor Brian Wynne
as Associate Director in Lancaster. Brian was an original
CESAGen co-applicant and Principal Investigator on two
Flagship Projects among others. Brian’s work has covered
risk assessment and perceptions, public understanding of
science, and sociocultural shaping of science. He will
provide intellectual leadership, support and development
across the whole Centre, especially in the areas of changing
forms of knowledge production, and modes of public
engagement with science. This formalises and extends his
previous role, including further integration of CESAGen’s
work with national and international networks, and of
genomics with other domains. He will lead the integration, in
CESAGen’s next phase, of political economic perspectives
on the epistemic, social and sustainability implications of
new forms of knowledge production. His role parallels
Professor Paul Atkinson’s Associate Directorship in Cardiff;
and with Dr Mairi Levitt continuing as Deputy Director in
Lancaster, the appointment represents an expansion of
CESAGen’s directorate. 
New Editor for Genomics, Society
and Policy (GSP) www.gspjournal.com
Stuart Blackman, based at the ESRC Genomics Forum, has
taken over as Managing Editor for the Network’s peer
reviewed online journal, Genomics, Society and Policy
(GSP). Providing an outlet for interdisciplinary research on
the social, ethical and legal aspects of genomics and related
emergent technologies such as nanotechnology and stem
cell research, GSP is free, open access and publishes three
times a year. For further information on submissions, or
GSP’s special themed editions contact Stuart on 0131 651
4742 or email managingeditor@gspjournal.com.
Egenis Visiting Professor appointed to Health
Ethics Committee
Professor Paul Griffiths has been appointed to the
prestigious Australian Health Ethics Committee; the AHEC;
a national policymaking body for bioethics. Paul is a visiting
professor spending approximately one month per year at
Egenis. The AHEC develops guidelines for the conduct of
medical research involving humans, monitors Human
Research Ethics Committees, and promotes public debate
on health issues.
A health psychologist to start in Egenis
Health psychologist Hannah Farrimond has joined Egenis.
Hannah will be working on a joint project between Egenis
and the primary care teams at Peninsula Medical School and
Nottingham University studying the history of familial heart
disease. The project is funded by the Genetics Based Health
Services Programme at the Department of Health. 
Hannah has worked on both qualitative and quantitative
projects and has a particular interest in mixed methodolo-
gies. She is also interested in exploring social meanings and
norms surrounding health behaviours connected with class
and socio economic status. 
www.centres.ex.ac.uk/egenis/staff/farrimond
Egenis fellow to become a clinician
Egenis research fellow Ruth Hall has moved on to start her
studies in medicine at Queen Mary’s, University of London.
In Egenis Ruth studied clinician-patient communication
about family history of heart disease. As a farewell present
the Egenis and Primary Care teams gave her a Littman
stethoscope as well as Ann Summers gift vouchers to
enhance dual-use of the equipment. 
People
Ruth Hall
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Have your say
Agree with this issue’s Editorial? Provoked by any other articles? Is there a subject or issue you’d like to see featured?
We’d like you to ‘Have Your Say’ so why not let us know what you think? 
Contact the editors by writing to: 
Editor, Genomics Network Newsletter, ESRC Genomics Policy and Research Forum, St John’s Land, Holyrood Road,
Edinburgh, EH8 8AQ or email gnn@ed.ac.uk
Stem Cell Appointments
Egenis has appointed two Research Associates, Susanne
Weber & Katrin Gehring, for a period of 2 years to work on
the ESRC funded project Stem Cell Research in Context.
A Comparative Study on the Dynamic Relationship Between
Science, Medicine, and Society. The study seeks to
compare the ways in which different regulation of stem cell
science in the UK and Germany affects the science
conducted and vice versa.
At Innogen, Stephen Bates arrives from the Department of
Political Science & International Studies, University of
Birmingham. His research interests encompass the political
economy of the life science industries; political and social
change; and the sociology of the body.
He joins the project at a busy time as the team completes 17
discussion groups with scientists working in the field of stem
cell research, primary healthcare workers, patient groups
and a number of community-based groups. Further small
discussions, based on a more interactive model bringing
different people and communities together, are planned for
the autumn and the project’s website -
www.talkingstemcells.ed.ac.uk - was launched recently.
CESAGen contribution to UNESCO conference
Dr Mina Bhardwaj, a researcher from CESAGen, was
invited to give a plenary talk at this year’s UNESCO
Asia-Pacific Conference on Bioethics Education which took
place on 26-28 July in Seoul, Korea. The main focus of the
conference was on enhancing both public awareness of
bioethics in a global era, and the “bioethics literacy” of
scientists and  medical experts. Mina’s talk was entitled
“Multidisciplinary bioethics: tensions and approaches to
education”.
Professor Irene Leigh awarded OBE
Professor Irene Leigh, who is an active member of the
Innogen Stakeholder Panel, received an OBE for services for
medicine in the Queen's Birthday Honours list.
Professor Leigh is head of Cancer Research UK's skin
tumour laboratory and joint research director of Bart's and
the London School of Medicine. Professor Leigh received
medical training at the London Hospital Medical College and
specialised in dermatology at postgraduate level. She spent
two years lecturing at the University of Dar es Salaam in
Tanzania before returning to work as registrar and senior
registrar in London. She became a consultant dermatologist
in 1983 and established the Cancer Research UK Skin
Tumour Laboratory in the same year. Her principal work has
been in the field of keratinocyte biology and she has made
many contributions to our understanding of non-melanoma
skin cancer.
Visiting Research Fellows Programme
The Forum continues its successful Visiting Research
Fellows programme over the next few months by welcoming
Dr Evan Willis (Professor of Sociology, La Trobe University,
Australia), Professor Alan Petersen (Professor of Sociology
and Research Coordinator, School of Law and Social
Sciences, University of Plymouth), Dr Joseph Graves Jr,
(Professor Evolutionary Biology/ Life Sciences, North
Carolina State University) and Jenny Reardon (Assistant
Research Professor of Women's Studies and Institute of
Genome Sciences and Policy scholar at Duke University).
For details of events and activities associated with this
programme, please visit www.genomicsforum.ac.uk/events
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My current research is looking at how the condition known
as Metabolic Syndrome is understood and shaped by the
various actors involved, ranging from physicians and
dieticians, to patients and even celebrity chefs. My early
interviews with members of the medical profession and lay
public often illicited the following response ‘what is
Metabolic Syndrome?’ Therefore, if you are reading this and
thinking, ‘I’ve never heard of it’, you are not alone. And if you
have heard about it, then the marketing departments of the
GI diet industry and ‘Big Pharma’ will be very pleased. 
It was first described by Prof. Gerald Reaven (an endocrinol-
ogist at Stanford University) in 1988. He had noticed that
certain biomedical abnormalities such as high blood
pressure, high cholesterol, high insulin levels and lateral
obesity often cluster together in the same patient. He gave
this newly described phenomenon the name Syndrome-X,
and suggested that the underlying cause was insulin
resistance.1 Subsequently, at least fourteen different names
have been used to describe the condition however, within
the medical and scientific communities, the term Metabolic
Syndrome is now generally accepted. It is worth noting that
Professor Gerald Reaven prefers to use the term ‘Insulin
Resistance Syndrome’ and, particularly in the United States,
the term ‘Prediabetes’ is frequently used in the same context
as Metabolic Syndrome.
There have been many different symptoms put forward as
diagnostic criteria for Metabolic Syndrome. This has resulted
in a number of attempts by different medical organisations to
define the condition, for example the World Health 
Organisation (WHO) came up with a preliminary definition in
1998. This was followed by a US National Institutes of
Health (NIH) backed set of diagnostic criteria in 2001, the
ATP-III Guidelines, which became the ‘gold standard’.
Then in 2005, the International Diabetes Federation (IDF),
attempted to create a new consensus definition. 
Metabolic Syndrome overlaps a number of different
stakeholder areas and border disputes between them have
been common, with for example diabetologists versus
cardiologists; the health food industry versus ‘Big Pharma’;
and between cardiologists in the United States continuing to
use their own ATP-III definition rather than adopting the new
IDF consensus definition. But even this picture is too
simplistic, with individuals within the same stakeholder
groups often holding differing views. Therefore, the
Metabolic Syndrome field is a complex network of different
definitions, diagnoses and stakeholder groupings influenced
as much by cultural and societal factors, as by scientific and
medical developments. 
Even so, this condition might still have gone largely
unnoticed had it not been for the so-called obesity crisis
which reached  epidemic proportions in the West by the late
1990’s. At the same time there was a  worrying rise in the
number of people suffering from the so-called Western
lifestyle diseases such as diabetes and heart disease.
The symptoms seen in the Metabolic Syndrome, such as
high blood pressure, high cholesterol and high insulin levels
seem to perfectly match those observed in many obese and
overweight individuals. Since insulin resistance is often  
METABOLIC 
SYNDROME
In recent years Metabolic Syndrome has
become a significant public health issue but,
asks Chris Chatterton, what do people really





associated with obesity, this gave the medical profession a
probable underlying cause. Therefore, the Syndrome went
from being an obscure observation, to a ‘hot new disease’,
in a comparatively short space of time, with media and
celebrity attention.2
Obesity rates have continued to soar in the West and
Metabolic Syndrome has also become a problem in many
developing countries, which have experienced ‘rapid
westernisation’ in recent years. Public health messages
encouraging people to eat healthily and take more exercise
seem in the main to have gone unheeded. Individuals from
socially and economically deprived backgrounds are
particularly at risk, and have often been the hardest groups
to reach.  Governments have therefore come under 
increasing pressure to introduce more effective public health
programmes to tackle the problem. It is against this 
background that Metabolic Syndrome has become a useful
weapon in the fight against obesity, with experts believing,
rightly or wrongly, that people are more likely to make
lifestyle changes if they are told they have a Syndrome,
rather than being told they are just overweight.
This has led to accusations that Metabolic Syndrome is an
example of the medicalisation of obesity, which further 
reinforces the widely held belief that everyone who is 
overweight is unhealthy.3 In their rush to demonise obesity,
many health campaigners have been economical with the
truth, in the mistaken belief that a few white lies are justified
in their battle against obesity. However, this strategy may
well backfire, when the complexity of the situation is better
understood and people start to ignore these simplistic 
health messages.
Nevertheless, Metabolic Syndrome is now seen as a
significant public health issue by experts and the wider
community and has many influential backers. However, a
number of concerns have been raised as to whether
Metabolic Syndrome is a bone fide medical condition.
In September 2005, the American Diabetes Association
(ADA) and European Association for the Study of Diabetes,
released a joint statement which raised questions about an
attempt by the IDF to create a new consensus definition and
about the entire clinical validity of the condition. 
These concerns have been strongly dismissed by vested
interests in the field and  the popularity of Metabolic 
Syndrome has remained largely unaffected. 
Therefore, the scientific and medical communities, along
with the diet and pharmaceutical industries, have been given
free reign to shape the Metabolic Syndrome. One of the
most surprising aspects of this situation has been the total 
lack of a true ‘patient voice’. This is probably because  
physicians have been reluctant to use the Metabolic
Syndrome diagnosis meaning that too few patients are able 
to relate to the term to make a ‘patient voice’ viable.        
Also, whilst many of the diabetes and heart disease charities
have also been raising awareness about Metabolic
Syndrome within their own communities any coherent
‘patient voice’ that has developed has been too diverse to
have any real impact. It is also clear that there are many
different struggles taking place over Metabolic Syndrome,
which reflect the various underlying power relationships’
involved. This in many ways follow a broadly Foucauldian
pattern, with a complex web of stakeholders all trying to
make the condition ‘their own’.  
Therefore, is Metabolic Syndrome just another ‘Big Pharma’
creation? I think the answer to that question is both yes and
no, because while it is certainly true that ‘Big Pharma’ has
been able to influence how the Syndrome is seen, the
medical and scientific communities have been equally adept
at promoting the condition for their own benefit.  The diet
industry has also been instrumental in raising public
awareness of Metabolic Syndrome. Having talked to many
different experts, I am convinced that these symptoms do
cluster in certain individuals and it is a bone fide
phenomenon. However, along with many other sceptics,
I am not sure how useful this additional information is for
doctors or patients trying to deal with the condition.
There is no guarantee that early detection and use of
preventative measures will stop future health problems from
developing. I am uncomfortable about the close relationship,
however innocent, that appears to exist between the
commercial sector (pharmaceutical and diet industries) and
the medical and scientific community, especially in relation
to the funding of continuing medical education (CME) and
clinical research. Yet, these worries are not only confined to
Metabolic Syndrome but can also be applied to many other
conditions in today’s commercially driven medical
environment.
References
1 Reaven GM. Banting lecture 1988: role of insulin resistance in human
disease. Diabetes. 1988; 37: 1595 – 1607.
2 Matthew Herper. Inventing a New Heart Disease. Forbes,  17/6/2004, Vol.
173, Issue 13.
3 Joanna Brietstein. The Making of a New Disease. Pharmaceutical Executive.
Jan 1, 2004.
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The books in this series, all based on original
research, explore the social, economic,
political, legal and ethical consequences of
the new genetic sciences. The series is based
in the ESRC’s Centre for Economic and Social
Aspects of Genomics (CESAGen) at Cardiff
University and Lancaster University and is
published by Routledge. CESAGen is the
largest UK investment in social science
research on the implications of these
innovations, and is thus ideally placed to
become one of the primary outlets for
research in these multiple fields. With a mix of
research monographs, edited collections,
textbooks and a new handbook, this series
will be a major contribution to the social
analysis of new genetic technologies, their
applications, implications and consequences.
We are currently seeking book proposals from
across the academic community to add to the
series. 
Forthcoming Publications
Governing the Transatlantic Conflict over
Agricultural Biotechnology: Contending
Coalitions, Trade Liberalisation and
Standard Setting.
Joseph Murphy, Oxford University and 
Les Levidow, The Open University
This book analyzes the EU-US conflict over GMOs and uses
it to explore the governance of new technologies. Going
beyond common stereotypes of regulatory differences and
their origins, this key book examines the trade conflict
through contending coalitions of policy actors operating
across the Atlantic.  
Murphy and Levidow provide new insights by elaborating
critical perspectives on global governance, issue-framing,
standard-setting and regulatory science. In their
comprehensive yet accessible book, the approach they take
will appeal to undergraduate and post-graduate students,
academics and policy-makers alike, in the fields of political
science, international relations, economics, development,
science and technology studies. 
The book will be on sale from July 2006: 224pp 
Hb: 0-415-37328-X: £65.00
The CESAGen Book Series also have the following titles
forthcoming: 
New Genetics, New Social Formations 
Edited by Peter Glasner, Paul Atkinson and Helen
Greenslade, Cardiff University
An edited collection exploring the multiple ways in which
new genetic technologies cut across a range of public
domains and private lifeworlds. This volume reflects the rap-
idly changing scientific, clinical and social environments
within which new social formations are being constructed
and reconstructed. The complex challenges that the new
technological options pose are examined in such diverse




The GM Debate. Risk, Politics and Public Engagement
Tom Horlick-Jones, Nick Pidgeon and Wouter Poortinga,
Cardiff University and John Walls, Gene Rowe and 
Tim O’Riordan, University of East Anglia
This book gives a unique and systematic account of key
aspects of the government sponsored debate on the
possible commercialization of ‘GM’ crops in the UK.
The authors produce a conceptually-informed and
empirically-based evaluation of the debate, drawing upon
detailed observation of both public and behind-the-scenes
aspects of the process, the views of participants in debate
events, a major MORI-administered survey of public views,
and details of media coverage.
September 2006
Hb: 0-415-39322-1 £65.00
CESAGen Genetics and Society 
BOOK SERIES
                         
New Genetics, New Identities 
Edited by Paul Atkinson, Peter Glasner and Helen
Greenslade, Cardiff University
New genetic technologies and their applications in
biomedicine and clinical settings have important implications
for social identities in contemporary societies. This volume
addresses transformations in collective and personal identity
from a variety of national, disciplinary and empirical
standpoints, and analyses the social implications of
advances in genetic technologies for identity formation in a
period of rapid scientific and social change. 
October 2006 
Hb: 0-415-39407-4 £65.00
Local Cells, Global Science. Embryonic Stem Cell
Research in India 
Peter Glasner, Cardiff University and Aditya Bharadwaj,
University of Edinburgh
One of the first studies of an exciting new development in
global biotechnology, this cutting edge text examines the
extent of the transnational movements of tissues, stem cells,
and expertise in the developing governance framework of
India. Documenting the impact of local and global
governance frames on the everyday conduct of research,
this groundbreaking book traces the journey of ‘spare’
human embryos in IVF clinics to public and private




Human Cloning in the Media 
Joan Haran and Jenny Kitzinger, Cardiff University and
Maureen McNeil and Kate O’Riordan, Lancaster University
Cultural representations of the ‘human genome’ have been
channelled through the imagery of and debates about
human cloning since the launch of the Human Genome
Project and the revelation of the birth of Dolly the Sheep.
This channelling has generated a rich and complex
discursive terrain in which key preoccupations and tropes
travel across and between various media forms and genres.
This book provides a multi-dimensional analysis of this
crucial phase in the development and exploration of human
cloning and related developments in genomics, giving due
attention to the mediation this has involved.
April 2007
Growth Cultures. Life Sciences and Economic
Development
Philip Cooke, Cardiff University
Biotechnology is now a pervasive influence in healthcare,
agro-food, environmental and energy industries.
This groundbreaking book is the first comparative analysis of
the relative strengths of global bioregions.  The author
assesses new theorisations of the role of scientific and
research knowledge in economic development, and shows
how the bioregions, their research institutes and both large
multinationals and small biotechnology firms have created a
globalized world of interconnected bioregions. 
June 2007
Hb: 0-415-39223-3 £70.00
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Proposal forms, guidelines and further information on the Genetics and Society Book Series are available from Helen
Greenslade, CESAGen, Cardiff University. GreensladeH@Cardiff.ac.uk
Series Editors: Paul Atkinson, Associate Director, CESAGen, Cardiff University; Ruth Chadwick, Director, CESAGen, Cardiff
University; Peter Glasner, Professorial Research Fellow, CESAGen, Cardiff University; and Brian Wynne, Associate Director,
CESAGen, Lancaster University.
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Genetic information is considered unusual, because it is
immutable throughout the lifecourse, sometimes determines
or predicts a future illness, has implications for relatives, and
may fuel social stigmas or psychological anxieties.  As a 
consequence individuals are often offered counselling before
genetic testing, and genetic test results are protected by
special data protection measures.
However, as genetic research has progressed it has been
asked whether all genetic information is equally sensitive.
Policy institutions, such as the Human Genetics
Commission, have suggested that pharmacogenetic tests
and tests for low, preventable genetic risk factors should not
be considered special. However, there are no studies on
whether people perceive such tests as unusual or not.
We asked people (42), who had been tested for a usually low
risk genetic susceptibility to deep vein thrombosis (DVT),
whether they thought the test was special. Many people
perceived the test as ordinary, much like a cholesterol test.
They said they thought it was less serious than a test for
genetic predisposition to breast cancer or non-genetic
diagnostic tests for diabetes, leukaemia or HIV. However,
some people were worried or confused about the test.
What makes a test special?
The main reason people thought the test was not so serious
was because they believed DVTs could be prevented.
They had stopped taking the contraceptive Pill and hormone
replacement therapy and had taken special precautions
during long flights, pregnancy and surgery. They had not
changed their lifestyle.
Even if people considered DVTs frightening, they also
perceived them as sudden events, from which one will
recover.  Several stated that they would worry more about a
cancer risk. Because the susceptibility was associated with
low risk, only few people had witnessed close relatives die
from or become seriously and chronically ill because of
a DVT.
These findings suggest that genetic tests that detect
susceptibilities to disease that are perceived as preventable
are not necessarily seen as special.
However, some people, who often had experienced several
DVTs or had close relatives, who had experienced DVTs with
serious complications, were more worried about the
condition. Many people also had a poor understanding of
the genetic test and its results; seven individuals were
unaware of having had the genetic test. Individuals, who
were poorly informed, were not necessarily more worried
about the test, but they often said that they were unsure of
whether they were doing the right things to prevent DVTs.
ARE GENETIC TESTS
SPECIAL?
Genetic information is usually considered
special or exceptional, having more
far-reaching implications than other types of
medical information. We asked individuals,
who had been tested for a low risk genetic
susceptibility to deep vein thrombosis, if they
thought the test was special. Many people did
not think so.
Dr Paula Saukko
Senior Research Fellow, Egenis
RIGHT: The genetic test for Factor V Leiden, which indicates a low risk
susceptibility to deep vein thrombosis, is one of the most common genetic
tests in the UK, even if it is rarely talked about. The pink Factor V Leiden test
tubes crowd the fridge in the local molecular genetics laboratory in Exeter.
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Implications for policy
Our study indicates an emerging way of understanding
genetic information not as revealing “in depth” knowledge
about one’s health or identity but as occasionally relevant
surface information, which is used to make specific
decisions about health.
These findings lend support to suggestions that genetic
testing for low risk susceptibilities could be performed in
mainstream medicine without special measures, such as
counselling offered by clinical genetics. The people
interviewed had not received specialist genetic counselling
via clinical genetic services. It could be that being referred to
a genetic test by a general practitioner or a consultant
haematologist made the test seem more ordinary.
However, the views of those patients, who had a strong
personal or family history of DVTs or who were worried and
poorly informed highlight that genetic information may worry
or confuse people. The views of these people warn against a
laissez-faire policy on genetic testing.
Generally our findings suggest that individuals may
experience genetic susceptibilities rather differently
depending on the perceived severity and preventability of the 
disease, personal and family histories of the disease and
level of education. Thus, the personal implications of any
susceptibility tests that may become available in the future
should be evaluated on a case by case basis paying
particular attention to experiences of vulnerable groups, who
are at a higher risk, more worried or less educated. 
Reference
Saukko, P.M., Richards, S.H., Shepherd, M.H., Campbell, J.L. 2006. 
Are genetic tests exceptional? Lessons from a qualitative study on 
thrombophilia, Social Science and Medicine, 63, 7, 1947-59.    
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Dr Gill Haddow, joined Innogen as a research
fellow in 2004 after completing a PhD on
Organ Transplantation and Donation: 
The Paradox of Gifting and Dis/Embodiment,
working with a multi-disciplinary team 
evaluating NHS 24 and as an ESRC post 
doctoral fellow in the University of Edinburgh’s
Sociology department. She is currently looking
at public consultation on the Scottish Family
Health Study. This programme is part of
Generation Scotland, which ultimately aims to
create more effective medical treatment based
on gene knowledge.
How did you end up working at Innogen?
Chance, really. I was coming to the end of an ESRC
Post-doc, based in the Sociology Department at Edinburgh
University, and found out a job was coming up here, at
Innogen, looking at public engagement for the Generation
Scotland project. I nearly blew the interview, though, as I
was so nervous - just talked, and talked, and talked.
Embarrassing when I think of it now!  
What are your research interests?
They vary depending on the research projects that I am
working on. I guess I am most interested in ideas about
embodiment (our relationship with ourself/body) and also our
relationships to other selves/bodies.  I've always been a bit
of a 'sunshine' sociologist with a tendency to look on the
bright side of life.  Although recently I have been having
some ‘control’ and ‘power’ tendencies which am a little
worried about. 
Who would be interested in your current
research?
My current empirical work on DNA databases is most
obviously important to the organisations who are funding this 
research to find out what folks think about Generation 
Scotland. It will also interest the organisers actually running
the project, who will want to know likely participation rates
etc.  Hopefully, the findings will be at least interesting, if not
important, in relation to the current vogue on public
consultation. They might also contribute to the little we know
about the role of the family in taking part in genetic research
such as DNA databases - an area I wouldn’t mind doing
more research in.
What is the most satisfying part of your job?
It’s got to be getting to work on some topical, challenging
and interesting social science research i.e. the evaluation of
NHS 24, family accounts of cadaveric organ donation and
the current work on DNA databases.  I've been pretty lucky
in that respect really.  I also find satisfaction in the process
of research itself – getting results (especially ones that you
never expect) and knowing that the job was done well and
you’ve contributed to knowledge.  I like getting ‘eureka’
moments, too, but they don’t happen so often.  
What is most frustrating?
Having too little time and limited funding; the lack of security
for a contract researcher;  having a whack of books and
journals sitting on the desk that I never seem to get round to
reading.  
What do you feel have been your key 
achievements?
I know it’s a bit of a cliché, but being here is bit of a
achievement in itself.  I’d had various jobs (hairdresser,
children's shoe-fitter, chip-shop fryer) and was a mature
student when I was accepted at Edinburgh University to do
joint honours in Philosophy/Psychology.  Actually getting the
qualifications in Sociology, going on to do a PhD and a
post-doc, making a career out of something that I really
enjoy doing and getting to work with some spot-on people –
it’s all good.
Where would you like to be in 10 years time?
I am still working on the 5-year plan! I haven't really thought
that far ahead but hopefully I’ll be doing more of what I am
doing at the moment; probably dabbling in some teaching.
Also, getting a few more projects under my belt – maybe
running a few.  Who knows?  I’ll be keeping my options
open. 
Dr Gill Haddow has recently published research about the attitudes of people
in Scotland to organ donation and views about DNA databases as part of




                   
Governing Genomics
Interdisciplinary Perspectives on 
the Regulation of the Biosciences
25-27 January, 2007 University of Exeter, UK
Conference Theme
Genetic and genomic information 
continue to transform the life sciences
and the application of this knowledge is
progressively interwoven with everyday
life. It is often presumed that biosciences
and biotechnologies require new or
specific modes of governance, and this 
assumption appears to motivate many
regulatory regimes. But is the 
governance of genomics special? If so,
what makes it special? What modes of
regulation are currently emerging? 
Does ‘the public’ have a special role to
play in the governance of genomics?
Call for Papers
We invite contributions from scholars and
practitioners in science and medicine,
social science, law, and philosophy.
We particularly encourage contributions
from those involved in governance who
want to exchange ideas with scholars
working in the field.
A poster session will provide a forum for
the presentation of a wide range of
research projects.
Abstracts for presentations and posters
are invited on all areas of the life
sciences including stem cells, gene
therapy, genetic testing, genetically
modified crops, systems biology, plant
genomics, animal genomics, human
genomics, animal breeding,
xenotransplantation, pharmacogenomics,
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Deadline for abstract submission: October 2006.
Registration Fee: Standard £150, Student £75.
Contact: egenis@exeter.ac.uk; +44 (0)1392 269141
For submission of abstracts for presentations or posters, delegate 
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